Notably, evidence from prodromal disease cohorts suggests that NfL levels begin to rise years before clinical onset in several disorders: up to 12–24 months in ALS [17] and even earlier in AD and Parkinson’s disease (PD) [18–20]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.